Interleukin 29

Template:PBB

Interleukin-29 (IL-29) is a protein that in humans is encoded by the IL29 gene that resides on chromosome 19.^[1]^[2]

IL-29 is a member of the helical cytokine family and is a type III interferon.^[3] It is also known as IFNλ1 and is highly similar in amino acid sequence to the IL-28, the other type III interferon. IL-29 plays an important role in host defenses against microbes and its gene is highly upregulated in cells infected with viruses. IL29 is not present in the mouse genome.

References

^ "Entrez Gene: interleukin 29 (interferon".
^ Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (January 2003). "IL-28, IL-29 and their class II cytokine receptor IL-28R". Nat. Immunol. 4 (1): 63–8. doi:10.1038/ni873. PMID 12469119.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Vilcek J (January 2003). "Novel interferons". Nat. Immunol. 4 (1): 8–9. doi:10.1038/ni0103-8. PMID 12496969.

Pagliaccetti NE, Eduardo R, Kleinstein SH, et al. (2008). "Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication". J. Biol. Chem. 283 (44): 30079–89. doi:10.1074/jbc.M804296200. PMC 2662072. PMID 18757365.{{cite journal}}: CS1 maint: unflagged free DOI (link)
Li MC, Wang HY, Wang HY, et al. (2006). "Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells". Acta Pharmacol. Sin. 27 (4): 453–9. doi:10.1111/j.1745-7254.2006.00292.x. PMID 16539846.
Megjugorac NJ, Gallagher GE, Gallagher G (2009). "Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)". J. Leukoc. Biol. 86 (6): 1359–63. doi:10.1189/jlb.0509347. PMID 19759281.{{cite journal}}: CS1 maint: multiple names: authors list (link)
UzÃ© G, Monneron D (2007). "IL-28 and IL-29: newcomers to the interferon family". Biochimie. 89 (6–7): 729–34. doi:10.1016/j.biochi.2007.01.008. PMID 17367910.
Hou W, Wang X, Ye L, et al. (2009). "Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages". J. Virol. 83 (8): 3834–42. doi:10.1128/JVI.01773-08. PMC 2663280. PMID 19193806.
Magracheva E, Pletnev S, Kotenko S, et al. (2010). "Purification, crystallization and preliminary crystallographic studies of the complex of interferon-lambda1 with its receptor". Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 66 (Pt 1): 61–3. doi:10.1107/S1744309109048817. PMC 2805539. PMID 20057073.
Stoltz M, KlingstrÃ¶m J (2010). "Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection". J. Virol. 84 (18): 9140–8. doi:10.1128/JVI.00717-10. PMC 2937636. PMID 20592090.
Brand S, Beigel F, Olszak T, et al. (2005). "IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression". Am. J. Physiol. Gastrointest. Liver Physiol. 289 (5): G960–8. doi:10.1152/ajpgi.00126.2005. PMID 16051921.
Pekarek V, Srinivas S, Eskdale J, Gallagher G (2007). "Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner". Genes Immun. 8 (2): 177–80. doi:10.1038/sj.gene.6364372. PMID 17252004.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Li M, Liu X, Zhou Y, Su SB (2009). "Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses". J. Leukoc. Biol. 86 (1): 23–32. doi:10.1189/jlb.1208761. PMID 19304895.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Jordan WJ, Eskdale J, Boniotto M, et al. (2007). "Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)". Genes Immun. 8 (1): 13–20. doi:10.1038/sj.gene.6364348. PMID 17082759.
Wang J, Oberley-Deegan R, Wang S, et al. (2009). "Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to influenza A infection". J. Immunol. 182 (3): 1296–304. doi:10.4049/jimmunol.182.3.1296. PMID 19155475.
Lasfar A, Lewis-Antes A, Smirnov SV, et al. (2006). "Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma". Cancer Res. 66 (8): 4468–77. doi:10.1158/0008-5472.CAN-05-3653. PMID 16618774.
Osterlund P, Veckman V, SirÃ©n J; et al. (2005). "Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells". J. Virol. 79 (15): 9608–17. doi:10.1128/JVI.79.15.9608-9617.2005. PMC 1181545. PMID 16014923.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Maher SG, Sheikh F, Scarzello AJ, et al. (2008). "IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity". Cancer Biol. Ther. 7 (7): 1109–15. doi:10.4161/cbt.7.7.6192. PMC 2435218. PMID 18698163.
Mennechet FJ, UzÃ© G (2006). "Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells". Blood. 107 (11): 4417–23. doi:10.1182/blood-2005-10-4129. PMID 16478884.
Wolk K, Witte K, Witte E, et al. (2008). "Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes". J. Leukoc. Biol. 83 (5): 1181–93. doi:10.1189/jlb.0807525. PMID 18281438.
Novak AJ, Grote DM, Ziesmer SC, et al. (2008). "A role for IFN-lambda1 in multiple myeloma B cell growth". Leukemia. 22 (12): 2240–6. doi:10.1038/leu.2008.263. PMC 2771776. PMID 18830264.
Witte K, Gruetz G, Volk HD, et al. (2009). "Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines". Genes Immun. 10 (8): 702–14. doi:10.1038/gene.2009.72. PMID 19798076.
Rauch A, Kutalik Z, Descombes P, et al. (2010). "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study". Gastroenterology. 138 (4): 1338–45, 1345.e1–7. doi:10.1053/j.gastro.2009.12.056. PMID 20060832.

This immunology article is a stub. You can help Wikipedia by expanding it.

[entrez-1] "Entrez Gene: interleukin 29 (interferon".

[pmid12469119-2] Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (January 2003). "IL-28, IL-29 and their class II cytokine receptor IL-28R". Nat. Immunol. 4 (1): 63–8. doi:10.1038/ni873. PMID 12469119.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid12496969-3] Vilcek J (January 2003). "Novel interferons". Nat. Immunol. 4 (1): 8–9. doi:10.1038/ni0103-8. PMID 12496969.

[1]

[2]

[3]

References

Further reading